Loading candles…
Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company specializing in the development, manufacturing, and commercialization of differentiated, high-value, complex generic and specialty formulations. Originally engaged in contract research, the company transitioned into a specialty products firm. Its operations encompass the entire drug lifecycle, including research and development, commercial manufacturing, and front-end marketing. Rubicon primarily serves the regulated U.S. market, focusing on delivering complex pharmaceutical formulations. No information is available on the company's founders, key management, subsidiaries, or stock listings.
This page is a live market overview for RUBICON RESEARCH LIMITED (RUBICON) on the NSE. As a listed security, RUBICON RESEARCH LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for RUBICON before placing trades on tick2trade.
As of the latest feed, RUBICON last traded at ₹1,553.2 on NSE, up ₹19.8 (1.29%) from the previous close of ₹1,533.4. Today's session range is ₹1,530.1 – ₹1,574, against a 52-week band of ₹570.75 – ₹1,589.7. Traded volume today stands at 98.12K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for RUBICON in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether RUBICON is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for RUBICON RESEARCH LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in RUBICON. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated RUBICON option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 29 May 2026 |
| Results - Q3-FY25 | To consider and approve the financial results for the quarter and nine months ended December 31, 2025 | 3 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.